Samir Ounzain, Haya CEO
A new RNA startup looks to reimagine heart treatments, with eyes set on Entresto
When Samir Ounzian left London a decade ago to study a little-understood branch of the genome at a Swiss lab, he wasn’t sure what he would find. Known as long-non-coding RNA, these sections were translated into looping rings of RNA — hence the name — but didn’t actually translate into proteins, and no one was quite sure how many there were or precisely what they were doing.
“We didn’t expect anything at the time,” Ounzian told Endpoints News, “because we didn’t really understand how frequent they were in the genome.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters